Article

Exploring Recent Developments in the Treatment of Patients With Hormone Receptor– Positive Breast Cancer

A select group oncology experts met to engage in a virtual discussion workshop moderated by oncologist Erika Hamilton, MD. The overall objectives were to review recent data on therapeutic advances in HR+ BC. This article summarizes data from recent trials in early HR+ and TNBC; HR+ metastatic BC, focusing on use of CDK4/6 inhibitors in the first line and second line and beyond; and promising new endocrine therapies that may represent the future direction of HR+ cancer treatment.

Related Videos
Jennifer Keating Litton, MD
Ruth M. O’Regan, MD
Stephanie L. Graff, MD
Related Content